Healthcare >> Analyst Interviews >> December 15, 2014
Stretched Valuations in Biotech Require Cautious Approach
Stefan Quenneville is an Equity Analyst for Morningstar, covering biotechnology companies. Mr. Quenneville has more than a decade of experience in the investment industry. Before joining Morningstar in 2013, he was a Senior Analyst for Stanton Asset Management in Canada. Previously, he was Vice President of health care research for Macquarie Group Limited, a global investment bank headquartered in Australia. He has also covered health care for other leading Canadian investment banks including Orion Securities — acquired by Macquarie — and Desjardins Securities. Mr. Quenneville began his career as a Consultant for the World Bank as part of a satellite and Web-based distance education project called the African Virtual University. He has also worked as a Management Consultant serving a range of clients, including technology, media and retail companies, international organizations, and nonprofits. Mr. Quenneville holds a bachelor’s degree in biology and environmental sciences, and an MBA with a concentration in finance from McGill University. He also holds the Chartered Financial Analyst designation. Profile
TWST: To start out, can you introduce yourself by giving us a snapshot of your coverage?
Mr. Quenneville: I'm a Biotech Analyst at Morningstar. I cover a number of biotech